In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Baxter announces plans to spin off biopharma operations as Baxalta

Executive Summary

Baxter International Inc., which announced in March its intention to split into two publicly traded companies--one focused on biopharmaceuticals, the other on medical products--in a tax-free distribution to shareholders, revealed it plans to spin off the Baxter BioScience biopharma operations as Baxalta Inc., a publicly traded company that will list on the NYSE under the symbol BXLT.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Divestiture

Related Companies